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Introduction 
 
Western culture has a tendency to value binaries and discreet categories that 
separate its social structure and provide a sense of order and organization. The value 
placed on binaries and categories may be advantageous in some aspects, but when it starts 
to infringe upon the legal and medical rights of individuals not easily placed in either 
binary category, it can become less advantageous. 
A baby is usually classified as either male or female shortly after birth, and all future 
legal, social, and economic actions and rights of that individual are more or less decided 
according to this classification. A problem with this system arises when children are born 
that do not neatly fit into either classification. These intersex individuals may be treated as 
abnormal in many spheres of their lives, which may have detrimental effects on their 
psyches. In the past, children determined to have ambiguous genitalia, defined as not fitting 
into either sexual classification, have often undergone infantile surgery in order to correct 
the ambiguity. In many ways, this surgical correction has had a major influence on the 
social and legal futures of these individuals, since a significant portion of Western culture 
depends on maintaining a sexual binary. One could say Western society may need to be 
more widely educated regarding the occurrence of medical conditions that may result in 
ambiguous genitalia and how to effectively integrate effected individuals into legal and 
social systems. 
Because medical professionals are classifying the sex of each individual that is born 
and are faced with how to best treat intersex conditions in the context of a patient’s 
physical, psychological, and legal needs, the medical community may need to consider 
adopting a strategic guide for effectively treating intersex individuals. The first section of 
this paper presents a few of the predominant genetic conditions that affect sexual 
development compared to typical sexual development. The second section aims to discuss 
how individuals with these conditions are typically approached in a clinical environment 
and discuss potential improvements in treatments. The final section examines a few 
societies in which intersex individuals are effectively integrated into the legal and social 
spheres and how they may serve as examples for how Western society might improve its 
treatment and classification of intersex individuals. 
 
 
 
I. 
 
Typical sexual development follows a specific pathway involving multiple genes, 
hormones, and organs over a considerable length of time. The presence and expression of 
certain genes only determine whether ovaries or testes will develop. The rest of sexual 
differentiation depends upon the characteristic secretions of the gonads that develop.  
Undifferentiated urogenital ridges are present in both male and female embryos 
until the seventh week of gestation. At the seventh week, the sexual-determining region of 
the Y chromosome (SRY) is expressed in those individuals with a Y-chromosome, and they 
will eventually develop into males.1 The absence of the SRY gene leads to ovarian 
development and will eventually result in a female phenotype. Before gonads begin to 
develop, a double genital duct system consisting of Wolffian and Müllerian ducts as well as 
a common external orifice exist in all embryos. As gonads develop, the single-duct system 
will differentiate and develop while the other degenerates.  
As testes develop, they begin to secrete the steroid hormone testosterone, which is 
manufactured in the Leydig cells, and a peptide hormone called MIS (Müllerian-inhibiting 
substance), which is manufactured in the Sertoli cells.1 The expression of the gene that 
encodes MIS is induced by an SRY-associated protein and thereby accompanies testicular 
development directly.1 Testosterone secreted from the testes induces the differentiation of 
the Wolffian ducts into the vas deferens, epididymis, ejaculatory duct, and seminal vesicles. 
In combination with dihydrotestosterone (DHT), a derivative of testosterone formed by the 
enzyme 5-alpha-reductase, testosterone induces the fusion of the labioscrotal fold to form 
the scrotum.1 It also stimulates the enlargement of the genital tubercle to form the penile 
glans tissue. The urogenital fold develops into the urethral groove and external anal 
sphincter, and the embryological cloaca develops into the bladder, urinary ducts, 
bulbourethral glands, and prostate.1  
In females, neither MIS nor testosterone is typically produced because no Y 
chromosome accompanied by an SRY gene is present. Therefore, Müllerian ducts 
differentiate into the Fallopian tubes and uterus without an ovarian hormone signal, and 
the Wolffian ducts degenerate in the absence of testosterone and MIS.1 In typical female 
development, the genital tubercle develops into the clitoris, and the urogenital fold 
develops into the labia minora/vestibule and anal sphincter. The labioscrotal fold develops 
into the labia majora, and the embryological cloaca develops into bladder, urinary ducts, 
and vagina.1 
Pseudovaginal Perineoscrotal Hypospadias (PPSH), XX and XY sex reversal, 
Androgen Insensitivity Syndrome (AIS), and Congenital Adrenal Hyperplasia (CAH) are just 
a few frequently encountered genetic conditions in which the typical process of sexual 
development is altered, producing an atypical phenotype. 
Pseudovaginal Perineoscrotal Hypospadias (PPSH), previously referred to as male 
pseudohermaphroditism, refers to a condition involving a genital configuration in which 
the urethral opening is located in the perineoscrotal region potentially accompanied by an 
incompletely closed genital opening resembling a small, shallow vagina.  PPSH arises from 
a 5-alpha reductase enzyme deficiency. This enzyme converts testosterone to DHT in the 
testes of typical males, and therefore a deficiency in males can lead to the development of 
external genitalia resembling that of a typical female. The karyotypes of individuals with 
PPSH are typically 46, XY.2 The SRY gene is usually present, which would typically lead to 
testicular differentiation and development. However, mutations in the SRD5A2 gene on the 
short arm of the second chromosome or the SRD5A1 gene on the fifth chromosome cause a 
translational error in manufacturing one form of the 5-alpha-reductase enzyme.2 The 
mutations typically found in the SRD5A2 gene are multiple base deletions or missense 
mutations at positions 197 or 212.3  
The external genitalia of individual with PPSH are often ambiguous at birth, and the 
phenotype could include perineoscrotal hypospadias and a blind pseudovaginal pouch 
mentioned before.2 Individuals with 5-alpha-reductase deficiency are typically reared as 
females if a blind pseudovaginal pouch is present, and additional symptoms are usually not 
evident until the body undergoes alterations associated with puberty. At puberty, 
masculinization including typical male habitus, muscular development, voice change, 
phallic enlargement, and semen production can occur due to the formation of a small 
amount of DHT. Individuals may also have a small prostate and develop a scanty beard. 
Amenorrhea and a lack of breast development at puberty may also be signs of this 
condition.2 
Biochemically, 5-alpha-reductase converts testosterone to DHT, reducing its steric 
strain, or the strain caused by the repulsion of electrons that are too close together. 
Molecules tend to assume the configuration where all electrons are equally spaced and 
flatter, and decreased steric strain allows DHT to bind to its receptors more easily.4 
Because the 5-alpha-reductase enzyme is defective, appropriate DHT transformation to a 
configuration with less steric strain is greatly inhibited. Testosterone and estrogen levels as 
well as testicular histology in individuals with PPSH usually resemble readings expected of 
typical males. This suggests that testosterone is converted into other substances to prevent 
negative feedback from inducing overproduction of testosterone. Müllerian structures are 
usually absent in these individuals, and Wolffian structures can be completely 
differentiated into the epididymis, ejaculatory ducts, and seminal vesicles.5 Viscous and 
concentrated semen resulting from a small prostate and seminal vesicles, as well as 
micropenis, may be present.5 
Two forms of 5-alpha-reductase deficiency have been suggested by the work of 
Leshin et al. (1978).6 One form is postulated to be the result of the aforementioned 
structural alteration of 5-alpha-reductase as evidenced by an abnormal dissociation 
constant for its substrate . The second form is paradoxically characterized by undetectable 
5-alpha reductase activity in biopsy specimens but a normal dissociation constant for its 
substrate, testosterone.6 5-alpha-DHT levels in these individuals are low, but 5-alpha-DHT 
is present in basal amounts, so some masculinization occurs.7 
Individuals with 5-alpha-reductase deficiency typically choose to adopt a male 
gender identity at puberty, probably because the effects of testosterone in the brain can 
override sociocultural factors.6 Therefore, many of these individuals may opt to undergo 
sexual reconstructive procedures. High dose androgen therapy has been effective in 
enhancing virilization and therefore improving self-image and sexual performance for 
individuals who self-identify with the male gender.8 
Sex reversal, previously referred to as true hermaphroditism, is another condition 
resulting in atypical sexual development. It can occur in karyotypic males or females. A 
diagnosis of complete sex reversal is rare, but it is based on the presence of a portion of the 
SRY gene at Yp11.31 and the presence of some degree of both ovarian and testicular tissue. 
In 46, XX individuals, sex reversal can arise from a translocation of a part of the Y 
chromosome containing the SRY gene onto an X chromosome.9 Phenotypically, XX 
individuals may resemble a typical male, but because only the SRY gene is present, not 
accompanied by the gene encoding the H-Y antigen, 46, XX individuals still exhibit many 
phenotypic characteristics that resemble a typical female.9 There are no Müllerian 
structures, but bilateral scrotal or maldescended ovotestes that produce both ova and 
spermatozoa are usually present.10 Individuals with genetic sex reversal are usually 
infertile. Clinical comparisons to individuals with Kleinfelter’s Syndrome patients revealed 
that 46, XX individuals with genetic sex reversal were also significantly smaller in stature.11 
Short stature is common even though IGF1 and IGFBP2 levels are usually normal.12 
Nonrandom X-chromosome inactivation ratios are common in the gonads of 46, XX 
males as the SRY gene translocated from the little arm of the Y chromosome to the little 
arm of an X chromosome may ensure the transcription of that chromosome by encouraging 
the hypomethylation of its 5’-flanking region.13 In one case, however, reciprocal 
translocation of the SRY gene on the little arm of the Y-chromosome to the big arm of the X-
chromosome may have resulted in the loss of X telomeric sequences and the subsequent 
differential inactivation of the X chromosome with the SRY gene.14 
In 46, XY individuals, genetic sex reversal can arise from either point mutations or 
deletions of the SRY gene.15 Phenotypically, individuals exhibit a phenotype mostly 
resembling that of typical females as normal uteri, fallopian tubes, and external genitalia 
are usually present, but many atypical secondary sex characteristics such as bilateral streak 
gonads that are misshapen and histologically homogenous are usually present 
accompanied by amenorrhea.16 
Because genes on the X-chromosome as well as chromosomes 5, 9, 10, 12, and 17 
have been shown to affect 46, XY sex reversal, the condition may exist in X-linked or 
autosomal recessive forms.17 If mutations in any of these genes cause complete gonadal 
dysgenesis, defined as a loss of gonadal germ line cells, the resulting condition is classified 
as Swyer’s syndrome. Those with the Sporadic Testicular Agenesis (STAS) form of Swyer’s 
syndrome do not have the H-Y antigen that is produced from the expression of the H-Y 
gene typically found on the Y chromosome. Those with the Familial Testicular Agenesis 
(FTAS) form do not have the H-Y antigen but exhibit an X-linked recessive inheritance. 
Those with Familial Testicular Dysgenesis (FTDS) have the H-Y antigen but exhibit streak 
gonads and a phenotype resembling that of a typical female.17 
A hypoestrogenized vagina and cervix are common in XX inviduals. These 
individuals are usually tall, and they may have an enlarged clitoris and a high incidence of 
neoplasia in the streak gonads.18 There may be evidence that X and Y loci collaborate in 
determining the typical male phenotype in XY individuals, and there may be a gene on the X 
chromosome that blocks the function of the H-Y antigen and consequently inhibits typical 
male phenotypic development in these individuals.19 
Androgen Insensitivity Syndrome (AIS) is another condition resulting in atypical 
sexual development. As its name suggests, AIS is the result of a decreased ability of 
androgens to bind to their receptors and induce their typical cellular response, and because 
androgens are in their greatest amounts in genotypic males, symptoms are most severe in 
genotypic males. Androgen insensitivity usually occurs because testosterone cannot 
effectively bind to the androgen receptors. This may be due to an abnormality in the DHT 
receptor, an inefficiency of the receptor-DHAT complex, a decreased affinity of testosterone 
for the receptor, or a decreased amount of receptors present.20 Phenotypic variability in 
the effected population occurs because of a mutation in the AR gene on the long arm of the 
X chromosome that codes for the androgen receptor.21 Point mutations and deletions 
associated with neighboring genes are common, but evidence for inversions that cause a 
break in the AR gene has also been found.22 
The SRY gene induces testicular development and subsequent MIS and testosterone 
secretion when it is present. MIS causes the Müllerian ducts to degenerate, but because the 
Wolffian ducts and external structures cannot detect the androgens secreted by the testes, 
the signal needed to induce differentiation, the Wolffian ducts degenerate as well, and the 
external structures develop to resemble those of a typical female. Inguinal testes are 
usually the result. The typical neonatal testosterone surge is dampened because the 
hypothalamic-pituitary axis (HPA) cannot respond to testosterone, and positive feedback 
to drastically increase testosterone levels cannot be stimulated.23 Insulin-like growth 
factors (IGF) are involved in mediating testosterone action and the growth of genital tissue, 
and IGFs are probably synthesized in genital tissue in response to a testosterone-induced 
signal cascade. Since testosterone cannot bind and initiate the typical signal to induce IGF 
synthesis, IGF1 levels are usually low in these individuals, resulting in a subsequent 
decreased bone mass density (BMD).24 Gynecomastia, a blind vagina, absent uterus, and 
female adnexa are common, but most cases are presented when amenorrhea becomes 
evident or an inguinal hernia is presumed and determined to be inguinal testes.  
Because there can be a variability in receptor dysfunction, there are a few different 
types of androgen insensitivity. Partial AIS, in which androgen receptors are only slightly 
insensitive to testosterone, can result in hypospadias, gynecomastia, and micropenis as 
expected of general AIS. However, variability in external genitalia phenotype is exhibited as 
higher concentrations of testosterone may saturate slightly insensitive androgen receptors 
and induce cellular responses similar to typical responses.25 Incomplete AIS, in which 
androgen receptors are not completely desensitized to androgens but do not have the 
capacity to induce typical cellular responses to an adequate degree, can result in clitoral 
enlargement, virilization, the dorsal fusion of the labioscrotal folds, some spermatogenesis, 
and only partial androgen responsiveness. Because of these signs, the incomplete form may 
be mistaken as PPSH, but androgen sensitivity tests can be used to confirm AIS.26 Testes 
are usually removed soon after an AIS diagnosis because of a high risk of cancer associated 
with inguinal testes. 
Chymerism in heterozygous 46, XX females and linkage to other X chromosome 
genes suggest AIS exhibits a simple X-linked inheritance pattern.28 The protein typically 
produced from the transcription and translation of the AR gene activates the expression of 
other genes. This ability depends on the structure of the N-terminal domain encoded in 
exon 1 of the gene, which contains polymorphic CAG repeats. A smaller number of repeats 
corresponds with a heightened ability of the AR protein to activate other genes involved in 
cell growth and metabolism, possibly resulting in a higher risk of prostate cancer.27 
Topical androgen gel therapy exhibits a potential to be successful in treating 
individuals with partial or incomplete AIS that self-identify as male. However, according to 
a study of 14 women, clinical patients have a tendency to express complete satisfaction 
with their rearing, gender assignment, sexual function, and psychosexual development 
based on their answers to a questionnaire and a psychosexual analysis and do not seek 
gender reassignment surgery.29 
In contrast to AIS, which results from the decreased ability of tissue to detect the 
presence of androgens and thereby respond to them, Congenital Adrenal Hyperplasia 
(CAH) is characterized by the overproduction of androgens, and therefore the hyper-
masculinization of body tissues. CAH is the result of a problem defect in the cortisol 
synthesis pathway, most commonly the result of a mutation in the CYP21A2 gene on the 
short arm of chromosome six that encodes the 21-hydroxylase enzyme.30 This condition is 
therefore inherited according to an autosomal recessive pattern. A mutation in the 
CYP21A2 gene causes an abnormal translation of the enzyme 21-hydroxylase, a 
misconfiguration of the enzyme, and a subsequent deficiency in enzymatic activity. The 
enzyme cannot convert 17-OHP to 11-deoxycortisol in the cortisol synthesis pathway and 
therefore halts cortisol production.30 A decrease in cortisol production results in decreased 
negative feedback to the HPA, resulting in increased adrenocorticotropic hormone (ACTH) 
secretion from the adenohypophysis. Increased ACTH overstimulates the adrenal cortex 
where cortisol is made in an attempt to increase cortisol production. As a result, because 
androgens are also produced in the adrenal cortex, androgen production increases, leading 
to masculinized external genitalia, postnatal clitoral enlargement, and early epiphyseal 
closure. Hyperpigmentation can also result from the hypersecretion of 
proopiomelanocortin (POMC) that accompanies the hypersecretion of ACTH and stimulates 
melanocytes.31 The gonads and internal genitalia of these individuals usually resemble 
those of typical males. Salt wasting can result because the disruption of the cortisol 
synthesis pathway at the 21-hydroxylase reaction also causes a decrease in aldosterone 
secretion from the adrenal cortex, a huge decrease in salt reabsorption in the kidneys and 
sweat glands, and therefore large amounts of salt excreted.32 
Because CAH can result from a disruption of any enzyme in the cortisol synthesis 
pathway, there are multiple types of CAH. The two main classifications are classic and non-
classic. The classic type is further divided into the salt-wasting form and the simple 
virilizing form. Because classic CAH can result in massive salt loss, the classic type is 
usually more severe while the symptoms of the non-classic type are usually only found late 
in life and are therefore less sever. In XX individuals, the classic form produces a phenotype 
that includes clitoromegaly and the fusion of the urethra and vaginal canal, therefore it is 
usually diagnosed at birth. XY individuals are more commonly diagnosed with the salt 
wasting form of classic CAH than XX individuals. XY individuals with the simple virilizing 
form of CAH display early virilization, potentially including an enlarged penis and body 
hair, between the ages of 2 and 4. Individuals with the non-classic form of CAH exhibit 
similar virilization to the classic type including infertility, oligomenorrhea, amenorrhea, 
polycystic ovarian syndrome, and acne in XX individuals, but symptoms occur later in 
adolescence. Sometimes symptoms never appear and the diagnosis is not made until the 
individual is tested for another condition from which atypical test results provide evidence 
for CAH. Individuals with CAH may also be behaviorally masculinized, so there is a high 
incidence of homosexuality in females.33 
Phenotypic variation is very broad in individuals with CAH because problems 
leading to CAH can arise during splicing, because the expression of 21-hydroxylase can be 
altered by genes in the renin-angiotensin systems, and because variable temporal and 
spatial gene expression occurs.34, 35 Bilateral testicular masses have been observed in XY 
individuals as well as clitoromegaly, gynecomastia, and labial fusion in XX individuals. Late 
sexual maturation, decreased incidence of pregnancies, and early onset osteoporosis 
because of decreased BMD are also common in XX individuals. Adrenal stimulation by 
ACTH can cause adrenal hypertrophy (increased adrenal area), tumors, and adrenal 
atrophy from exhaustive stimulation.36 Amygdala function may also be impaired by the 
hypersecretion of CRH in both XX and XY individuals leading to decreased emotional and 
fear responses.37 Low thyrotropin-stimulating hormone (TSH) has been observed because 
increased hypothalamic/pituitary/adrenal activity decreases TSH secretion, which also 
leads to decreased adrenomedullary function via epinephrine and norepinephrine.38 
Decreased levels of thyroxine from decreased TSH secretion leads to a decrease in the 
permissive action of thyroxine on epinephrine and can also disrupt glycemic control.39 
Testicular tumors or the impairment of Leydig cells as a result of decreased plasma 
testosterone can lead to decreased spermatogenesis, subsequent azoospermia, and poor 
semen quality in affected XY males as well.40 
A fourth cryptic form of CAH is characterized by typical 21-hydroxylase deficiency 
that is accompanied by no symptoms with the exception of an increased incidence of 
tumors.  
Amniotic fluid steroid analysis is only successful in diagnosing the salt-wasting form 
of CAH, but a first day urine analysis of 17-hydroxyprogesterone and androstenedione can 
provide an accurate diagnosis of all forms.41,42 Nighttime low dosage dexamethasone 
therapy can dissipate adrenal masses and restore fertility. It is recommended during 
pregnancy because it crosses the placenta quickly, has a long half-life, and has a large 
suppressive effect on ACTH, although it may affect verbal working memory and self-
perception.43 The non-classic form of CAH may be treated by adrenocorticosteroids 
potentially accompanied by adrenalectomy.44 
Non-classic CAH is the most frequent autosomal recessive genetic condition with an 
overall frequency of 1 in 5,000 births, although frequencies in Zurich are even higher and 
gene frequencies in Ashkenazi Jewish populations can reach 0.223.45 In contrast to the 
severe symptoms that can occur as a result of CAH, there is a heterozygote advantage for 
carriers due to the fact that cortisol levels are higher and therefore stress response is 
heightened and the individuals is therefore more efficient in coping with physiological 
stress.46  
 
 
 
II. 
 
Many conditions like the ones described in Part I are diagnosed as Disorders of 
Sexual Development (DSD), a general category that includes all conditions that result in 
atypical sexual development.  The treatment of these conditions can be very extensive, 
sometimes including hormone replacement, multiple surgeries, and a great number of 
medications. Historically, the sexual development of an individual along one of the two 
typical pathways is emphasized in medical professions, and therefore medical 
professionals are accustomed to treating patients classified as either male or female. 
Therefore, when a child is born with ambiguous genitalia or any number of other DSDs, 
many medical professionals may not be completely confident in how to treat these 
individuals. The pressure of potentially altering the physical, social, and psychological traits 
of these individuals combined with a low level of social and medical exposure to 
individuals with these conditions may make it difficult for medical professionals to know 
how to effectively treat them. Because the social structure of modern Western society 
includes such a distinct gender and sexual binary, doctors and other medical professionals 
are often unable to separate their concern with the social implications of intersex 
individuals and the medical consequences of certain DSDs for the individuals themselves. 
Most of these complications stem from a previously perceived necessity for immediate 
medical or surgical intervention when an individual with a DSD is presented as well as the 
customary practice of determining sex from only two options. 
 Some DSDs impose large health risks on the effected individuals and should be 
treated in a way that minimizes these risks and detrimental effects. For example, because 
CAH involves cortisol and aldosterone deficiencies and subsequent salt wasting, 
hypotension, dehydration, hyponatremia, hyperkalemia, and even death, immediate action 
to minimize these issues is medically necessary.47 Gonadal dysgenesis and hypospadias 
often accompanying DSDs result in higher frequencies of gonadoblastomas and urinary 
tract infections, which again should be treated to prevent detrimental health effects.48 But 
many other DSDs have little to no detrimental side effects. Patients with Androgen 
Insensitivity Syndrome (AIS) have a theoretical risk for gonadoblastomas, but this risk can 
be drastically reduced by simply removing the gonads in one surgical procedure.49 The 
effects of any treatment beyond what is medically necessary should be carefully 
considered.  
The treatment of many DSDs have been historically linked to social placement and 
gender socialization because intersex individuals often do not fit into male/female binary 
categories so relied upon in traditional Western medical practice. Before the late 1970s, 
there was a minimal focus on how to treat intersex patients effectively considering what 
was in the best interest of the patient. For example, infantile clitoroplasty in individuals 
with clitoromegaly has been very common to conform ambiguous genitalia to the shape, 
size, and configuration seen in typical females. This procedure was generally used in any 
case of genital abnormality, usually defined as a morphology that made it difficult to 
identify the presence of an adequate penis. Used in an effort to ensure the classification of 
these babies as female, these surgical procedures can potentially reduce the individuals’ 
genital sensations, which can be detrimental to their sexual pleasure, overall sexual 
satisfaction, self-image, and sexual performance, which can then lead to even more 
negative effects psychologically.  
 Any child born that had an atypical karyotype was considered a social and medical 
emergency. Following any infantile genital reconstruction surgeries, parents of the 
individual were advised to keep the nature of the condition confidential, and all intersex 
children were recommended to be reared as females as reductive surgery is quicker, easier, 
and cheaper than surgeries that required the addition of tissue.50 In addition to 
unnecessary infantile sexual reconstructive surgeries, past studies used to determine the 
severity of CAH were even illogically based on which gender-charged toys affected children 
played with rather than on biochemical or physical symptoms.33 
 In the late 1970s, however, Dr. Milton Edgerton at Johns Hopkins University and the 
University of Virginia started producing a bulk of scientific literature recommending 
proper clinical treatment of intersex and transsexual individuals, including the 
psychological and surgical facets of their treatments. He started to separate the social and 
medical aspects of individuals with DSDs and transgendered individuals. His goal was to 
make the medical aspects of treatment more objective and to construct a comprehensive 
list of standard guidelines for treating these conditions in an attempt to make the 
treatment of these individuals more fulfilling for the patients themselves in regards to their 
clinical health and psychological satisfaction. Before long, “gender dysphoria” became an 
official diagnosis for intersex or transgendered individuals who felt that their gender 
socialization did not correspond with the sex they felt they inhabited. Edgerton began 
calling reconstructive surgeries “sex-confirmation operations” rather than sexual-
reassignment operations. Advocacy groups of medical professionals and social advocates 
began to construct and modify the guidelines on how to treat these individuals in a clinical 
setting. Eventually, necessary reconstructive surgery needed to improve healthy body 
function such as the cosmetic correction of hypospadias, previously conducted to appease a 
social binary, was separated from the type of reconstructive surgery desired by the patient 
utilized to re-enter society as a member of their self-identified sex. Similarly, the use of 
infantile clitoroplasty and other unnecessary procedures to alter ambiguous genitalia were 
restricted.51 
 A shift to patient centered medicine involving transgendered patients or patients 
with DSDs altered the way these individuals were treated. Steps were taken to ensure that 
gender dysphoria was authentic by a “gender team” of medical professionals across many 
fields. Professional thoroughly presented patients with the risks involved in “sex 
confirmation operations” and were required to be declared physically and mentally fit for 
gender reassignment by a group of psychologists and surgeons before the process could be 
initiated. Preliminary real-life tests were conducted, requiring a patient to publicly and 
privately assume the role of the opposite gender to ensure adequate transitioning following 
irreversible surgery.51 Aesthetically satisfying cosmetic alterations were considered to be 
important, but proper functioning and sensation of surgically altered genitalia were 
considered very high priorities. Gender reassignment surgeries for transgendered men 
who identified as women aimed to produce a neovagina capable of intercourse and a 
sensate clitoris capable of inducing orgasms in order to maximize sexual satisfaction.52 
Genetic counseling services were also made available to inform the patient of their 
condition, and counseling was framed around being sensitive to the patient and explaining 
that their condition, although atypical, is normal and something that happened before they 
were born at no fault of their parents or themselves.53 
 Many legal battles then began to arise over how men and women who have 
undergone “sex-confirmation surgeries” should be categorized legally and who is legally 
responsible for children with DSDs. In 1999, the Constitutional Court of Columbia stated 
that children born with ambiguous genitalia were treated based on the wishes of their 
parents granted the parents were concerned for the wellbeing of the child, not 
themselves.50 Although a step in the right direction, a more considerate model for 
treatment was developed later. Milton Diamond and Keith Sigmundson developed an 
extensive list of guidelines that should be strictly followed when treating individuals with 
DSDs and/or infants that may mature to be transgendered. This list included a full and 
concise genital inspection at birth, a primary focus on major health risks such as electrolyte 
imbalances and hypospadias associated with CAH, and patience during the meticulous 
inspection. This model included full disclosure of information to the parents and an 
encouragement to seek counseling while being reminded the condition arose due to fault of 
no one. A focus on the affected patient was paramount in this model, and while sex might 
be classified due to the likelihood of how that individual would develop psychologically and 
physiologically, no major operations would be performed to solidify the classification. Once 
the patient is able to make informed decisions about his or her condition, then physical 
changes can be made provided they are eligible according to the aforementioned criteria. 
Diamond and Sigmundson’s model was built on communication and positive messages, an 
approach finely tuned to both the psychological and medically aspects of treatment. And 
their main point was that most intersex conditions do not necessitate major surgery for the 
patient to feel socially and psychologically fulfilled.54 This model is still widely used today, 
and has been modified to appeal to individuals in relation to their contexts. A book called 
Transgender Emergence also provides a very comprehensive guideline for an integrated 
treatment involving many sociocultural techniques to be used by health professionals and 
social workers to improve the quality of treatment for the patients.55 
 Presently, there are still many legal battles happening involving insurance coverage 
of sexual reassignment surgeries and other treatments regarding DSDs and transgendered 
identity. Twenty-eight states do not have explicit Medicaid regulations about coverage, 21 
states have explicit regulations excluding coverage, and those that do not have explicitly 
exclusive regulations do explicitly exclude cosmetic or experimental procedures.56 Of 
course, common legal arguments in favor of including “sex-confirmation surgeries” rest on 
the fact that reassignment surgery has been proven to be effective and fulfilling for the 
patient and that if denied surgery, a person’s psychological health may be negatively 
impacted.  
 Knowledge and awareness about how to treat DSDs and how to improve the 
psychological health of transgendered individuals should be emphasized in medical 
communities. Many individuals with AIS and other DSDs have had less than quality medical 
evaluations and have undergone marginalization by their healthcare professionals and 
therefore less than effective treatments.49 Sometimes, the biggest issue is how to cope with 
the social and psychological implications of DSDs, for example when doctors must decide 
how to manage masculinization at puberty of individuals with 5-Alpha Reductase 
Deficiency.  Patient-centered care that involves a multidisciplinary approach by medical 
and other support teams well versed in how to convey sensitivity toward these individuals 
is of the utmost importance.48 Because some intersex and transgendered individuals are 
undergoing changes that could potentially be traumatic, more follow up studies need to be 
conducted on how patients respond under these guidelines of care. Individuals need to 
supply informed consent on how they would like to be treated, which means some families 
may need to wait 10-15 years after their child is born with a DSD to make decisions about 
how to approach the condition medically if intervention is an option.50 
 Groups like the World Professional Association for Transgender Health (WPATH) 
constantly construct and revise the Standards of Care of intersex individuals. The 
Endocrine Society has created guidelines on how to properly diagnose DSDs and how to 
confer treatment. The Gay and Lesbian Medical Association (GLMA) aims to create a 
welcoming community of medical professionals prepared to treat DSDs and transgendered 
individuals, and Accord Alliance is an advocacy group for legal and social change 
surrounding the rights of transgendered individuals. Websites like YouthResource and 
Trans Basics are also immensely concerned with these individuals’ experiences in the 
doctor’s office.57 These groups and many like them are making great strides toward 
informing medical professionals and families of patients with DSDs on how to manage 
these conditions medically and socially.  A larger emphasis on integrating these methods 
into medical school curriculums as a part of sensitivity and ethical training has also been 
widely advocated.  
 Developing uniform standard guidelines for how to treat transgendered individuals 
and individuals with DSDs is becoming easier as the people developing them continue to 
consider the comfort and well being of the patient, but we must also be careful in realizing 
that within the diagnosis of gender dysphoria or any of the many DSDs, individuals can 
vary widely with regard to medical needs and psychological states of mind. Not every 
individual can be treated the same way and yield optimal results. Just as in other fields, 
each patient must be treated as an individual, and these guidelines may need to be 
modified depending on the particular patient’s needs. These challenges still comprise a 
large gray area of medicine that needs to be constantly modified and fine-tuned.58  
 The language used in the medical field regarding DSDs and intersex individuals also 
needs to be altered. Lee et al. (1996) proposed that a DSD should be redefined as a 
“congenital condition in which development of chromosomal, gonadal, or anatomic sex is 
atypical,” which emphasizes that DSDs are not abnormal or disorderly, simply atypical. The 
renaming of true hermaphroditism, male pseudohermaphroditism, and testicular 
feminization as sex reversal, PPSH, and AIS are also steps in the right direction as they 
reflect the physiological and clinical aspects of the condition rather than traditional social 
responses to these atypical phenotypes. The connotation that words carry in a diagnosis 
can have a great impact on how the effected individual views himself or herself when the 
condition is not under his or her control, so medical jargon is worth considering in 
reference to these conditions in order to conform to the guidelines set forth by Midgerton, 
Diamond and Sigmundson, and countless other organizations. 
 
 
 
III. 
 
Although Western society typically has a tough time integrating individuals into 
society who do not fit into the widely accepted male-female binary, many societies around 
the world have found it relatively easy and simple to effectively incorporate these 
individuals into society by reorganizing society rather than by reclassifying these 
individuals. Intersex or transgendered individuals are even greatly admired or considered 
divine in some societies. 
A significant percentage of the Dominican Republic population are effected by 5-
alpha reductase deficiency or PPSH described in Part I. These individuals are called the 
guevedoces, and as implied by the Spanish term roughly translated to “testicles at 12,” these 
individuals are born with ambiguous genitalia and raised as female until puberty, at which 
time they start to exhibit male secondary sexual characteristics including the descendance 
of testicles and penile growth. The guevedoces exhibit a typical male karyotype, but because 
of a lack or deformation of the 5-alpha reductase enzyme, these individuals are unable to 
convert testosterone to DHT.59 This form of 5-alpha reductase deficiency or PPSH has been 
classified as Type 2 Familial Incomplete Male Pseudohermaphroditism while Type 1 has 
been understood to be Reifenstein syndrome.60 PPSH is similar to Reifenstein syndrome 
but is characterized by autosomal inheritance and gynecomastia. It is characterized 
biochemically by a structural alteration of 5-alpha-reductase exhibited by an abnormal 
dissociation constant (Km) and low levels of enzymatic activity.6 
In the 1970s, Dr. Julianne Imperato-McGinley visited a small mountain village in the 
Dominican Republic to study the guevedoces and found that they composed about 2% of the 
general population.5 In Dominican society, she found that these individuals were legally 
and socially considered as a third sex. As their phenotypic transformations progress, the 
guevedoces assume a male gender role in society and usually identify as a heterosexual 
male with a common desire to father children despite being reared as females for over a 
decade. This major shift in gender association completely contradicted Money’s theory that 
gender identity becomes fixed at three years old by insinuating that gender identity can 
completely reverse at least until puberty.61 Dr. Imperato-McGinley’s findings also suggest 
that gender identity is partly biological and partly sociological. Therefore, she wonders if 
these individuals assume a male identity at puberty because they are pressured to by 
society or if they are biologically prone to undergo a shift in gender identity due to 
physiological and psychological changes. 
Regardless of the exact origin and cause of this gender shift, the classification of this 
subpopulation as a third sex in Dominican society provides a model for how sex and gender 
should be classified in Western culture. By recognizing the guevedoces as members of a 
separate sex, the people of the Dominican Republic recognize that a strict sexual 
dimorphism is not universal in humans.62 The sexual transformation of these individuals is 
welcomed by joyous celebrations and although these individuals may encounter slight 
stigmas as a statistical minority, they are at least acknowledged as a third group. They 
aren’t expected to fit into the strict sexual binary imposed by Western culture because they 
recognize that a strict sexual binary is inapplicable in nature, including the human species.  
The recognition of these individuals has not only had social implications, but 
medical ones as well. Once the physiological effects of 5-alpha reductase deficiency were 
identified and studied, pharmacological treatments for benign prostate hyperplasia were 
developed. The discovery of the trophic effects on the prostate by DHT led to the 
development of 5-alpha reductase inhibitors like finasteride and dutasteride were in order 
to treat prostate hyperplasia by replicating the physiological effects that 5-alpha reductase 
deficiency has on the prostate of the guevedoces.63 
 The Dominican Republic is not the only country or society that embraces intersex 
and transgendered individuals as a normal part of society. Native-American “two-spirits” 
who identify with both their feminine and masculine spirits are considered divine in many 
North American tribes. The hijra of India and south Asia are sometimes holy people and 
carry out many sacred rituals. They are even included in many holy texts as divinities. The 
nation of Bangladesh has officially recognized their classification as a third sex. A kathoey of 
Thailand is a transgendered, homosexual, or intersex individual that is regarded as a 
product of karma and is widely recognized as a master within the entertainment and 
fashion businesses. The list of societies who recognize and embrace the presence of 
intersex or transgendered individuals is not exhausted here, and they serve as beautiful 
examples for Western society, proving societies that recognize and integrate transgendered 
or intersex individuals as integral parts of society often flourish.  
 
 
 
Conclusion 
 
 Although it is often the genesis of social injustice towards intersex and 
transgendered individuals, the sexual dichotomy that is engrained in Western culture is not 
completely based on illusion. Sexual dimorphisms are very prevalent in nature and used to 
classify the members of the species. Body structures can be vastly different in males and 
females of different species. For example, the neuronal cluster of the hypothalamus is 
markedly larger in males than in females of humans.64 The purpose of this paper, however, 
is not to refute that strict sexual dimorphisms and dichotomies exist, but that in the wide 
variation of life, they should not be considered the only possibilities. And in a human 
context in which society is a major aspect of life, the sex of an individual that does not 
clearly fall into either category should not be the cause of being socially ostracized or 
labeled as abnormal. This philosophy can be extended to the variety of sexualities that exist 
in the human population as well. Evidence for linkage of human male homosexuality to a 
gene on the long arm of the X chromosome has been presented as well as a genetic 
mutation in fruit flies that causes homosexual male courtship behaviors.65,66 And it is 
widely accepted among scientists that a huge variety of sexualities is exhibited in the rest of 
the animal kingdom. Physiology is a result of a very large number of molecules interacting 
together in complex ways determined by the genetic code in each living thing. This complex 
interaction of molecules is the machine that manufactures the variety of life. And every 
molecule in every pathway provides an opportunity for change that should be considered 
natural and normal. Everything we are as a member of the animal kingdom is determined, 
in some part, by our biology, and our social abilities should not seek to override this fact 
but to embrace it. 
This paper has illustrated that there are many genetic and physiological origins of 
intersex conditions. Intersex and transgendered individuals, although statistically atypical, 
are not abnormal but naturally occurring individuals like any other individual that is 
considered typical. Medical standards acknowledging the rights of these individuals are 
transforming, and they should continue to be adjusted as more knowledge and experience 
is gained concerning how to effectively treat these individuals. Because sexual classification 
has dramatic effects on social integration, legal standing, a sense of sexuality, self-identity, 
and the overall sense of well being of an individual, these medical standards cannot be 
completely objective but must be continuously adjusted for each individual in the context 
of each individual’s life. The acknowledgement and respectful incorporation of these 
treatments into the medical field can initiate a shift in social stigmas surrounding these 
individuals and progress toward establishing a society in which all human beings are 
treated with respect. So many cultures around the world have adopted policies of equality 
and justice for these individuals in social, medical, legal, and religious spheres, and it is 
time for Western society to follow in these footsteps.  Every human being on earth has a 
certain amount of androgens and estrogens inside them, and the ratios of the two and the 
effects they have on the morphology of the body should not be considered a social 
emergency, but a social opportunity for progress and equality.  
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